Physician profile
Danielle Bouchard
NPI 1518549054
$1,248.82
in general payments reported to CMS, 2019-2025
22 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $203 · 2023: $465 · 2024: $275 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $170.32 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $153.61 | 2022-2025 | Lifevest |
| Amgen INC. | $124.07 | 2022-2023 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $123.34 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $97.11 | 2022 | |
| Silk Road Medical, INC. | $93.17 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Baxter Healthcare | $61.43 | 2024 | Floseal |
| Atricure, INC. | $47.50 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.42 | 2022-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $43.48 | 2023 | |
| Biosense Webster, INC. | $37.86 | 2023 | Carto 3 |
| Myriad Genetic Laboratories, INC. | $32.42 | 2023 | Myrisk |
| Regeneron Healthcare Solutions, INC. | $27.08 | 2023 | Evkeeza |
| Mindray Ds USA, INC. | $25.70 | 2024 | Te7 Max, Te X |
| Solventum Corporation | $24.45 | 2024 | Activ.A.C. |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lemaitre Vascular, INC. | $23.00 | 2024 | Trivex System |
| Lilly USA, LLC | $22.98 | 2025 | Zepbound, Mounjaro |
| Kestra Medical Technology Services, INC. | $22.78 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.23 | 2023 | Xarelto |
| Edwards Lifesciences Corporation | $18.28 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Daiichi Sankyo INC. | $18.21 | 2022 | |
| Abbvie INC. | $17.38 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Bouchard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.